Union Bancaire Privee UBP SA Purchases New Holdings in BioNTech SE (NASDAQ:BNTX)

Union Bancaire Privee UBP SA purchased a new position in BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,500 shares of the company's stock, valued at approximately $282,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Planning Capital Management Corp lifted its holdings in shares of BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after buying an additional 450 shares during the period. Blue Trust Inc. lifted its holdings in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after acquiring an additional 388 shares during the period. GAMMA Investing LLC lifted its holdings in BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company's stock valued at $74,000 after acquiring an additional 111 shares during the period. Clear Harbor Asset Management LLC purchased a new position in BioNTech in the third quarter worth about $210,000. Finally, Probity Advisors Inc. bought a new stake in shares of BioNTech during the 3rd quarter valued at about $216,000. Institutional investors own 15.52% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BNTX. Evercore ISI raised shares of BioNTech from an "in-line" rating to an "outperform" rating and raised their price objective for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. TD Cowen dropped their price target on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research note on Tuesday, November 5th. Wells Fargo & Company started coverage on BioNTech in a research note on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 price objective for the company. HSBC lifted their target price on BioNTech from $97.00 to $136.00 and gave the company a "buy" rating in a research report on Monday, October 7th. Finally, Berenberg Bank initiated coverage on BioNTech in a research report on Tuesday, November 19th. They issued a "buy" rating and a $130.00 price target for the company. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and a consensus target price of $142.72.

BioNTech Price Performance

Shares of BioNTech stock traded up $2.89 during trading on Friday, reaching $123.77. 865,445 shares of the stock traded hands, compared to its average volume of 674,925. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a market capitalization of $29.67 billion, a price-to-earnings ratio of -58.94 and a beta of 0.18. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The business has a fifty day simple moving average of $117.34 and a two-hundred day simple moving average of $107.19.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $514.08 million. During the same period in the prior year, the firm earned $0.73 EPS. The company's revenue for the quarter was up 38.9% on a year-over-year basis. Sell-side analysts expect that BioNTech SE will post -3.77 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.